Yamamoto, Takatsugu
Mizokami, Yuji
Yamashita, Takeshi
Akao, Masaharu
Atarashi, Hirotsugu
Ikeda, Takanori
Koretsune, Yukihiro
Okumura, Ken
Shimizu, Wataru
Suzuki, Shinya
Tsutsui, Hiroyuki
Toyoda, Kazunori
Hirayama, Atsushi
Yasaka, Masahiro
Yamaguchi, Takenori
Teramukai, Satoshi
Kimura, Tetsuya
Morishima, Yoshiyuki
Takita, Atsushi
Inoue, Hiroshi
Article History
Received: 10 November 2023
Accepted: 16 April 2024
First Online: 27 April 2024
Competing interests
: T. Yamamoto received remuneration from Viatris Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Janssen Pharma, Kissei Pharmaceutical, AbbVie, EA Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, and Biofermin Pharmaceutical, and research funding from Pfizer and AbbVie. Y. Mizokami has no conflicts of interest. T. Yamashita received research funding from Bristol-Myers Squibb, Bayer, and Daiichi Sankyo, manuscript fees from Daiichi Sankyo and Bristol-Myers Squibb, and remuneration from Daiichi Sankyo, Bayer, Pfizer Japan, and Bristol-Myers Squibb. M.A. received research funding from Bayer and Daiichi Sankyo, and remuneration from Bristol-Myers Squibb, Nippon Boehringer Ingelheim, Bayer, and Daiichi Sankyo. H.A. received remuneration from Daiichi Sankyo. T.I. received research funding from Daiichi Sankyo and Bayer, and remuneration from Daiichi Sankyo, Bayer, Nippon Boehringer Ingelheim, and Bristol-Myers Squibb. Y.K. received remuneration from Daiichi Sankyo, Bayer, and Nippon Boehringer Ingelheim. K.O. received remuneration from Nippon Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, and Medtronic. W.S. received research funding from Daiichi Sankyo, and Nippon Boehringer Ingelheim, and remuneration from Daiichi Sankyo, Pfizer Japan, Bristol-Myers Squibb, Bayer, and Nippon Boehringer Ingelheim. S.S. received research funding from Daiichi Sankyo, and remuneration from Bristol-Myers Squibb and Daiichi Sankyo. H.T. received research funding from Daiichi Sankyo and Nippon Boehringer Ingelheim, remuneration from Daiichi Sankyo, Bayer, Nippon Boehringer Ingelheim, and Pfizer Japan, scholarship funding from Daiichi Sankyo, and consultancy fees from Pfizer Japan, Bayer, and Nippon Boehringer Ingelheim. K.T. received remuneration from Daiichi Sankyo, Otsuka, Novartis, Abbott, Bayer, and Bristol-Myers Squibb. A.H. participated in a course endowed by Boston Scientific Japan, has received research funding from Daiichi Sankyo and Bayer, and remuneration from Bayer, Daiichi Sankyo, Bristol-Myers Squibb, and Nippon Boehringer Ingelheim. M.Y. received research funding from Nippon Boehringer Ingelheim, and remuneration from Nippon Boehringer Ingelheim, Daiichi Sankyo, Bayer, Bristol-Myers Squibb, and Pfizer Japan. T. Yamaguchi functioned as an advisory board member for Daiichi Sankyo and has received remuneration from Daiichi Sankyo and Bristol-Myers Squibb. S.T. received research funding from Nippon Boehringer Ingelheim and remuneration from Daiichi Sankyo, Sanofi, Takeda, Chugai Pharmaceutical, Solasia Pharma, Bayer, Sysmex, Nipro, NapaJen Pharma, Gunze, Kaneka, Kringle Pharma and Atworking. T.K., Y. Morishima, and A.T. are employees of Daiichi Sankyo. H.I. received consultancy fees from Daiichi Sankyo.